Form 4 for ELVN Enliven Therapeutics, Inc.
Accepted 2026-04-21 20:40:17 ET · period of report 2026-04-17 · accession 0001701247-26-000006 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-04-21 20:40 | 2026-04-17 | ELVN | Collins Helen Louise | Chief MEDICAL Off | M - OptEx | $2.48 | +5,000 | 30.0K | +20% | +$12.4K |
| DMT | 2026-04-21 20:40 | 2026-04-17 | ELVN | Collins Helen Louise | Chief MEDICAL Off | S - Sale+OE | $47.67 | -5,000 | 25.0K | -17% | -$238.4K |
| DT | 2026-04-21 20:40 | 2026-04-17 | ELVN | Collins Helen Louise | Chief MEDICAL Off | M - OptEx | $0.00 | -5,000 | 131.3K | -4% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-04-17 | M | A | 5,000 | $2.48 | 30,000 | D | — | — | (F1) The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. (F2) Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. |
| 2 | Common | Common Stock | 2026-04-17 | S | D | 140 | $45.81 | 29,860 | D | — | — | (F1) The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. (F3) This transaction was executed in multiple trades at prices ranging from $45.525 to $46.38. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. (F2) Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. |
| 3 | Common | Common Stock | 2026-04-17 | S | D | 2,419 | $47.39 | 27,441 | D | — | — | (F1) The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. (F4) This transaction was executed in multiple trades at prices ranging from $46.8218 to $47.8166. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. (F2) Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. |
| 4 | Common | Common Stock | 2026-04-17 | S | D | 2,441 | $48.06 | 25,000 | D | — | — | (F1) The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. (F5) This transaction was executed in multiple trades at prices ranging from $47.8303 to $48.4936. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. (F6) These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. |
| 5 | Derivative | Stock Option (right to buy) | 2026-04-17 | M | D | 5,000 | $0.00 | 131,268 | D | $2.48 · — to 2031-06-17 | 5,000 Common Stock | (F1) The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. (F7) All of the shares subject to this option are fully vested and exercisable as of the date hereof. |